Makita Shinichi
Department of Hematology, National Cancer Center Hospital.
Rinsho Ketsueki. 2023;64(6):504-513. doi: 10.11406/rinketsu.64.504.
Classic Hodgkin lymphoma (cHL) is one of the common subtypes of malignant lymphoma in Western countries. Although patients with HL showed unsatisfactory results in the 1960s, the clinical development in radiotherapy and chemotherapy based on several clinical trials over the last 50 years has made cHL a curable disease with a favorable outcome. As a result, late-onset treatment-related toxicities such as second primary malignancies and cardiac events are thought to be a significant issue especially in early-stage patients. To minimize the toxic effects while maximizing the antitumor efficacy, several clinical trials to evaluate response-adapted strategies using interim PET scans and novel agents, such as brentuximab vedotin (BV) and/or immune checkpoint inhibitor (ICI) are currently underway. In this review, the author summarizes currently available data on PET-adapted and BV and/or ICI-containing therapies for untreated cHL, and discusses their future prospects in cHL treatment.
经典型霍奇金淋巴瘤（cHL）是西方国家恶性淋巴瘤的常见亚型之一。尽管20世纪60年代HL患者的治疗效果不尽人意，但过去50年基于多项临床试验的放疗和化疗临床进展已使cHL成为一种可治愈且预后良好的疾病。因此，迟发性治疗相关毒性，如第二原发性恶性肿瘤和心脏事件，被认为是一个重大问题，尤其是在早期患者中。为了在最大限度提高抗肿瘤疗效的同时将毒性降至最低，目前正在进行多项临床试验，以评估使用中期PET扫描以及新型药物（如brentuximab vedotin（BV）和/或免疫检查点抑制剂（ICI））的适应性反应策略。在本综述中，作者总结了目前关于未经治疗的cHL的PET适应性治疗以及含BV和/或ICI治疗的可用数据，并讨论了它们在cHL治疗中的未来前景。
